Dashboard
Manage Tickers

KURA


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cantor-fitzgerald-reiterates-overweight-on-kura-oncology
Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 17:17:31

Cantor Fitzgerald analyst Li Watsek reiterates Kura Oncology (NASDAQ:KURA) with a Overweight.

jmp-securities-reiterates-market-outperform-on-kura-oncology-maintains-32-price-target
JMP Securities Reiterates Market Outperfor...
08/12/2024 14:08:48

JMP Securities analyst Reni Benjamin reiterates Kura Oncology (NASDAQ:KURA) with a Market Outperform and maintains $32 price...

hc-wainwright--co-reiterates-buy-on-kura-oncology-maintains-32-price-target
HC Wainwright & Co. Reiterates Buy on Kura...
08/12/2024 10:05:52

HC Wainwright & Co. analyst Joseph Pantginis reiterates Kura Oncology (NASDAQ:KURA) with a Buy and maintains $32 price t...

cantor-fitzgerald-reiterates-overweight-on-kura-oncology
Cantor Fitzgerald Reiterates Overweight on...
08/09/2024 15:29:08

Cantor Fitzgerald analyst Li Watsek reiterates Kura Oncology (NASDAQ:KURA) with a Overweight.

wedbush-reiterates-outperform-on-kura-oncology-maintains-37-price-target
Wedbush Reiterates Outperform on Kura Onco...
08/09/2024 14:11:06

Wedbush analyst Robert Driscoll reiterates Kura Oncology (NASDAQ:KURA) with a Outperform and maintains $37 price target.

stifel-maintains-buy-on-kura-oncology-lowers-price-target-to-26
Stifel Maintains Buy on Kura Oncology, Low...
08/09/2024 12:38:45

Stifel analyst Bradley Canino maintains Kura Oncology (NASDAQ:KURA) with a Buy and lowers the price target from $28 to $26.

kura-oncology-q2-2024-gaap-eps-059-beats-063-estimate
Kura Oncology Q2 2024 GAAP EPS $(0.59) Bea...
08/08/2024 20:41:11

Kura Oncology (NASDAQ:KURA) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $(0.63)...

kura-oncology-announces-fda-clearance-of-ind-application-for-ziftomenib-to-treat-advanced-gist-preclinical-data-suggest-combination-with-imatinib-could-resensitize-patients-and-induce-durable-responses-phase-1-study-to-begin-in-1h-2025
Kura Oncology Announces FDA Clearance Of I...
08/08/2024 11:38:01

hc-wainwright--co-reiterates-buy-on-kura-oncology-maintains-32-price-target
HC Wainwright & Co. Reiterates Buy on Kura...
06/24/2024 17:20:36

HC Wainwright & Co. analyst Joseph Pantginis reiterates Kura Oncology (NASDAQ:KURA) with a Buy and maintains $32 price t...

kura-oncology-presents-preclinical-data-on-diabetes-treatment
Kura Oncology Presents Preclinical Data on...
06/24/2024 11:43:23

Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision m...

jmp-securities-reiterates-market-outperform-on-kura-oncology-maintains-32-price-target
JMP Securities Reiterates Market Outperfor...
06/18/2024 13:11:06

JMP Securities analyst Reni Benjamin reiterates Kura Oncology (NASDAQ:KURA) with a Market Outperform and maintains $32 price...

jmp-securities-reiterates-market-outperform-on-kura-oncology-maintains-32-price-target
JMP Securities Reiterates Market Outperfor...
05/16/2024 16:56:18

JMP Securities analyst Reni Benjamin reiterates Kura Oncology (NASDAQ:KURA) with a Market Outperform and maintains $32 price...

hc-wainwright--co-reiterates-buy-on-kura-oncology-maintains-32-price-target
HC Wainwright & Co. Reiterates Buy on Kura...
05/14/2024 14:02:34

HC Wainwright & Co. analyst Joseph Pantginis reiterates Kura Oncology (NASDAQ:KURA) with a Buy and maintains $32 price t...

jmp-securities-reiterates-market-outperform-on-kura-oncology-maintains-32-price-target
JMP Securities Reiterates Market Outperfor...
05/06/2024 15:03:55

JMP Securities analyst Reni Benjamin reiterates Kura Oncology (NASDAQ:KURA) with a Market Outperform and maintains $32 price...

hc-wainwright--co-reiterates-buy-on-kura-oncology-maintains-32-price-target
HC Wainwright & Co. Reiterates Buy on Kura...
05/03/2024 19:53:40

HC Wainwright & Co. analyst Joseph Pantginis reiterates Kura Oncology (NASDAQ:KURA) with a Buy and maintains $32 price t...

wedbush-reiterates-outperform-on-kura-oncology-maintains-37-price-target
Wedbush Reiterates Outperform on Kura Onco...
05/03/2024 13:42:40

Wedbush analyst Robert Driscoll reiterates Kura Oncology (NASDAQ:KURA) with a Outperform and maintains $37 price target.

kura-oncology-q1-2024-gaap-eps-059-misses-055-estimate
Kura Oncology Q1 2024 GAAP EPS $(0.59) Mis...
05/02/2024 20:19:33

Kura Oncology (NASDAQ:KURA) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.5...

hc-wainwright--co-reiterates-buy-on-kura-oncology-maintains-32-price-target
HC Wainwright & Co. Reiterates Buy on Kura...
04/22/2024 17:45:18

HC Wainwright & Co. analyst Joseph Pantginis reiterates Kura Oncology (NASDAQ:KURA) with a Buy and maintains $32 price t...

kura-oncologys-ziftomenib-has-been-granted-fda-breakthrough-therapy-designation-for-relapsedrefractory-npm1-mutant-acute-myeloid-leukemia
Kura Oncology's Ziftomenib, Has Been Grant...
04/22/2024 11:32:03

hc-wainwright--co-reiterates-buy-on-kura-oncology-maintains-32-price-target
HC Wainwright & Co. Reiterates Buy on Kura...
03/06/2024 17:01:44

HC Wainwright & Co. analyst Joseph Pantginis reiterates Kura Oncology (NASDAQ:KURA) with a Buy and maintains $32 price t...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION